Technology | November 19, 2012

Hologic’s best-in-class solutions for breast screening, intervention and treatment, osteoporosis risk assessment and extremity imaging highlight its commitment to putting Patients First

3D mammography (breast tomosynthesis) system

U.S. Food and Drug Administration (FDA) in February 2011 and has been available in countries recognizing the CE mark since 2008. Hologic’s 3D mammography technology is available in 46 states and 29 countries outside the U.S.

Hologic’s 3D mammography system placed first in the digital mammography category in the KLAS 2012 annual survey of healthcare executives and clinicians. 3D mammography was recently selected by AuntMinnie as the “hottest clinical procedure” of the year for the third year in a row. AuntMinnie is the largest and most comprehensive community Web site for medical imaging professionals worldwide. In October, the Cleveland Clinic picked 3D mammography as one of the Top 10 Medical Innovations for 2013 at the Clinic's 10th annual Medical Innovation Summit.

Fifteen of the clinical papers and over 50 of the workshops, seminars, poster sessions and scientific papers to be presented at the conference are on 3D mammography (breast tomosynthesis).  Clinical presentations cover the use of tomosynthesis in screening and diagnostic applications.

Hologic is once again offering RSNA meeting attendees sixteen 75-minute sessions with hands-on experience reading 3D breast tomosynthesis images in combination with conventional and synthesized 2D images. Brief lectures will provide an overview of the technologies prior to the hands-on sessions. Each program will be taught by a leading breast imaging radiologist.  Conference attendees can register to take a workshop through the RSNA meeting web site.

Some of Hologic’s other advances in breast tomosynthesis on display at the conference include its tomosynthesis biopsy option for use with the Affirm™ biopsy guidance system and its C-View™ synthesized 2D image option. The tomosynthesis biopsy option is CE marked and is pending FDA clearance. The C-View Synthesized 2D image option received CE marking in 2011 and received a favorable vote for approval from an FDA Advisory Panel in October 2012. 

For more information: www.hologic.com


Related Content

News | Mammography

April 29, 2025 — iCAD, a global provider of clinically proven AI-powered cancer detection solutions, has announced a ...

Time April 29, 2025
arrow
News | Mammography

April 24, 2025 — GE HealthCare will feature its latest advancements in diagnostic accuracy and patient-centered breast ...

Time April 24, 2025
arrow
News | Artificial Intelligence

March 10, 2025 — Lunit, a provider of AI-powered solutions for cancer diagnostics and therapeutics, has published a ...

Time March 10, 2025
arrow
News | Artificial Intelligence

Feb. 19, 2025 — SimonMed Imaging and HeartLung Technologies have signed a strategic partnership to offer HeartLung's AI ...

Time March 04, 2025
arrow
News | Ultrasound Imaging

Jan. 28, 2025 — GE HealthCare recently announced it has received 510(k) clearance from the United States Food and Drug ...

Time January 29, 2025
arrow
News | Breast Imaging

Jan. 8, 2025 — ScreenPoint Medical has acquiredf Biomediq A/S, a research-based company focused on the research ...

Time January 10, 2025
arrow
News | Breast Imaging

Dec.11, 2024 — iCAD, Inc., a provider of clinically proven AI-powered cancer detection solutions, recently announced ...

Time December 18, 2024
arrow
News | Mammography

Dec. 5, 2024 — At RSNA 2024, Lunit and Volpara Health announced their unified vision, focusing on a comprehensive ...

Time December 05, 2024
arrow
News | Mammography

Nov. 26, 2024 — GE HealthCare has introduced the Pristina Via* mammography system designed to enhance the screening ...

Time December 02, 2024
arrow
News | Artificial Intelligence

Dec. 2, 2024 — Lunit recently unveiled follow-up findings from the ScreenTrustCAD trial. This study, conducted at Capio ...

Time December 02, 2024
arrow
Subscribe Now